Table 2.

sNKG2DL and S100B in sera from melanoma patients

nsMICA (pg/mL), mean (25%/75%)sULBP2 (pg/mL), mean (25%/75%)S100B (μg/L), mean (SE)
Controls5090.3 (6.0/109.5)2.6 (0.0/0.0)NA
    Gender
        Male3479.4 (9.0/109.5)1.9 (0.0/0.0)NA
        Female16113.6 (2.0/97.5)4.2 (0.0/0.0)NA
Patients208257.4 (185.0/344.0)*45.6 (0.0/53.5)0.71 (2.08)
    Gender
        Male106230.6 (172.0/347.5)45.0 (0.0/52.3)0.75 (0.24)
        Female102285.3 (190.0/340.8)46.2 (3.0/53.8)0.68 (0.17)
    Stage (American Joint Committee on Cancer)
        I/II25223.4 (114.0/325.0)0.0 (0.0/0.0)*0.07 (0.01)*
        III54190.9 (111.0/279.5)29.4 (0.0/42.8)*0.09 (0.02)*
        IV129291.8 (215.0/404.0)61.2 (13.0/69.0)*1.13 (0.24)*
    Tumor load
        Tumor-bearing117253.0 (195.0/350.0)63.4 (13.0/70.0)*1.20 (0.28)*
        Tumor-free91263.1 (153.0/327.0)22.7 (0.0/24.5)*0.24 (0.09)*

NOTE: Data for sNKG2DL are represented as mean (25% quartile; 75% quartile); data for S100B are mean (SE). Statistical analyses were done using the Mann-Whitney test (patients versus controls; males versus females; tumor-bearing versus tumor-free) and the Kruskal-Wallis test (differences between disease stages).

Abbreviation: NA, not analyzed.

  • *P < 0.0005.

  • P < 0.005.